EUCTR2021-002178-17-CZ进行中（未招募）1 期
A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-424 (dienogest 2.00 mg / ethinyl estradiol 0.02 mg) in the treatment of polycystic ovary syndrome (PCOS) versus placebo during 9 cycles
Chemo Research S.L.0 个研究点目标入组 367 人开始时间: 2022年6月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 367
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Two years postmenarcheal women of any ethnic origin between 18 and 40 years (inclusive at the time of enrolment), not seeking pregnancy.
- •2. Diagnosed with PCOS according to the following criteria:
- •a. Presence of hirsutism measured using an adapted mFG with a cut-off value of = 7 (at V1a only based on patient’s history or interview; to be determined only at Visit 1b)
- •b. Presence of one of the following criteria:
- •1. Oligomenorrhea (= 6 menses per year) while not using hormonal contraceptives
- •2. Polycystic ovaries defined as presence of 12 or more follicles measuring 2 - 9 mm throughout the entire ovary or an ovarian volume = 10 cm3 determined by ultrasound.
- •(Ovarian cyst are any fluid filled structure > 30 mm in diameter that persisted for more than 2 cycles and enlarged follicles are any structure similar to an ovarian cyst that did not persist).
- •3. Informed consent form (ICF) signed voluntarily before any study-related procedure is performed; indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study.
- •4. Body Mass Index (BMI): 18 kg/m2 = BMI < 35 kg/m2.
- •5. At screening, maximum systolic blood pressure (median value of 3 values) = 140 mm Hg and diastolic blood pressure (median value of 3 values) = 90 mm Hg.
- •6. Haematology and chemistry parameters, heart rate (HR) and electrocardiogram (ECG) within reference range, or showing no clinically relevant deviations, as judged by the investigator.
- •7. Willing to use trial medication for nine 28-day cycles.
- •8. Is consenting to use reliable nonhormonal contraceptive methods (condoms, female or male sterilisation or sexual abstinence) during the study from screening until the final examination visit.
- •9. Must be willing to avoid the use of all hair removal or growth procedures and products apart from shaving during the trial and to shave the hairs for a period of 14 days before the modified adapted mFG score will be determined during study participation.
- •10. Has a good physical and mental health as determined on the basis of medical history and general physical examination performed at screening.
- •11. Willing to adhere to the prohibitions and restrictions specified in the protocol and being able to comply with the use of the trial medication or the use of the trial diary.
- •12. Agrees to not participate in any other clinical trials during the course of this trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 347
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnancy or wish for pregnancy.
- •2. Breastfeeding women.
- •3. Current smoker with age = 36 years and/or with BMI > 30 kg/m² (at the time of trial enrolment)
- •4. Abnormal finding on pelvic, breast or intravaginal ultrasound examination that in the investigator’s opinion contraindicates participation in the trial.
- •5. Women = 21 years of age with a Papanicolaou (pap) smear reading low-grade squamous intraepithelial lesion (LSIL) or higher at screening (or 6 months prior to screening date). Subjects with atypical squamous cells of undetermined significance (ASC-US) can be included if they are negative for high-risk Human papilloma virus (HPV) strains. Subjects < 21 years of age do not require a Pap smear.
- •6. Poorly controlled diabetes (HgbA1c > 6.5%). Treatment with metformin is allowed only if it is expected to remain stable during the trial (defined as a stable dose for at least 3 months before V1a).
- •7. Anaemia (haemoglobin < 10 g/dL).
- •8. Subjects with disorders other than PCOS, that can result in menstrual irregularity and hyperandrogenism such as non-classic 21-hydroxylase deficiency, hyperprolactinemia, hypothyroidism, Cushing’s syndrome, nonclassical congenital adrenal hyperplasia and androgen-secreting tumours.
- •9. Known contraindication or hypersensitivity to ingredients or excipients of the IP, including:
- •a. Presence or risk of a venous thromboembolism (VTE)
- •b. Presence or risk of an arterial thromboembolism (ATE)
- •c. Presence or history of pancreatitis, if it is associated with severe hypertriglyceridemia
- •d. Presence or history of liver diseases in which liver function has not returned to normal (also Dubin-Johnson and Rotor syndrome)
- •e. Current or previous liver tumours
- •f. Known or suspected sex hormone-dependent malignant tumours (e.g., breast or endometrium)
- •g. Undiagnosed vaginal bleeding
- •h. Unexplained amenorrhoea
- •i. Concomitant use of medicinal products containing ombitasvir/paritaprevir/ritonavir or dasabuvir
- •10. Uncontrolled chronic concomitant diseases (i.e., not on a stable treatment dose for at least 2 months at the time of consent).
- •11. Severe Covid-19 disease or less than 3 months after hospitalisation due to a Covid-19 disease.
- •12. Evidence or history of alcohol, medication or drug abuse (within the last 12 months prior to consent).
- •13. Known or suspected human immunodeficiency virus (HIV) and/or hepatitis infection at screening.
- •14. Previous intake of hormonal contraceptives within the last 3 months prior consent or concomitant intake of hormonal contraceptives
- •15. Previous or concomitant intake of 5a-reductate inhibitors (e.g. flutamide) or similar inhibitors
- •16. Long-term treatment (longer than 7 consecutive days within a month prior to V1b) of any medication that might interfere with the efficacy of hormonal contraceptives.
- •17. Prohibited medication include the use of oestrogens, progestogens, strong microsomal enzyme-inducing drugs (intensive and moderate frequency).
- •18. Other prohibited medications include antiandrogens, insulin sensitizers or drugs that might interfere with blood pressure regulation, lipid profile or carbohydrate metabolism within the last 6 months prior to consent.
- •19. Administration of human chorionic gonadotropin (hCG) or intake of co-medication containing hCG within a month prior to V1b.
- •20. Inositol treatment within the last 3 months prior to consent.
- •21. Evidence or history of clinically significant psychiatric illness or suicide risk.
- •22. Planned surgery during the
研究者
相似试验
进行中（未招募）
1 期
Ivermectin to prevent SARS-CoV-2 (COVID-19) hospitalisation in subjects over 50EUCTR2020-005015-40-SKChemo Research S.L.832
进行中（未招募）
1 期
A clinical study in women suffering from endometriosis to test the drug LPRI-CF113 (drospirenone) during 6 months of treatmentEndometriosisEUCTR2021-001424-17-HUChemo Research S. L.236
进行中（未招募）
1 期
A clinical study in women suffering from endometriosis to test the drug LPRI-CF113 (drospirenone) during 6 months of treatmentMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2021-001424-17-SKChemo Research S. L.236
进行中（未招募）
1 期
A clinical study in women suffering from endometriosis to test the drug LPRI-CF113 (drospirenone) during 6 months of treatmentMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2021-001424-17-LTChemo Research S. L.236
进行中（未招募）
1 期
A clinical study in women suffering from endometriosis to test the drug LPRI-CF113 (drospirenone) during 6 months of treatmentMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2021-001424-17-CZChemo Research S. L.236